The platform, HCP Studies, will serve as a conduit to inform and encourage SMG physicians to participate in clinical research efforts throughout the group’s network. The platform was created in hopes of addressing the ongoing difficulty of finding patients to participate in clinical studies.
SMG already offers treatment options to patients through its clinical trials program, which is led by a research review committee and comprised of SMG physicians and staff, who manage all clinical trials, determine the scientific/ethical merits, and identify the potential impact of clinical research on patients.
Using Altura’s HCP Studies platform, SMG has active clinical trials open for enrollment in a broad range of disease states, including medical oncology, rheumatology, allergy/immunology, and neurology. Details and enrollment information can be found on the Clinical Research section of Summit Medical Group’s website.
“Conducting cutting-edge medical research, including clinical trials represents an important component of Summit Medical Group’s focus on comprehensive, patient-centered care. With more than 800 HCPs overseeing the care of over half a million active patients, we have broad-ranging capabilities for assisting in the advancement of medical research,” said Dr. Gary Pien, SMG’s medical director of research and clinical trials, in a statement.